Program
Varenicline
Also written as “varenicline”, “Varenicline Tartrate” and “varenicline (CP-526,555)”.
Its studies are mostly in Smoking Cessation · Dry Eye Syndromes · Smoking · Trigeminal Neuralgia · Cigarette Smoking, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizer | 320 open or running | phase 4since Jan 3, 2008 | Aug 29, 2005 | none ahead |
| Viatris | 60 open or running | phase 3since Jul 25, 2019 | Aug 15, 2018 | none ahead |
| Corxel Pharmaceuticals | 20 open or running | phase 3since May 13, 2022 | May 13, 2022 | none ahead |
| Rose Research Center | 20 open or running | phase 4since Jun 6, 2019 | Jun 6, 2019 | none ahead |
| Kriya Therapeutics | 11 open or running | phase 2since Apr 17, 2026 | Apr 17, 2026 | Feb 2029phase 2 · NCT07596485 |
| SRI International | 10 open or running | no phasesince Mar 8, 2006 | Mar 8, 2006 | none ahead |
Also a collaborator on its studies: GlaxoSmithKline.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 30 studies since Aug 29, 2005.
- Jun 8, 2011Phase 4 study in Smoking CessationPfizer · NCT01370356 · 1,510 enrolled · United States, Australia, Canada and more
- Oct 14, 2011Phase 4 study in Smoking CessationPfizer · NCT01456936 · 8,144 enrolled · United States, Argentina, Australia and more
- Apr 6, 2012Phase 4 study in Smoking CessationPfizer · NCT01574703 · 4,595 enrolled · United States, Argentina, Australia and more
- Aug 15, 2018Viatris's first study: phase 2 study in Dry Eye SyndromesNew to ViatrisViatris · NCT03636061 · 182 enrolled · United States
- Sep 26, 2018Phase 2 study in Dry Eye SyndromesViatris · NCT03688802 · 18 enrolled · United States
- Mar 11, 2019Phase 2 study in Dry Eye SyndromesViatris · NCT03873246 · 123 enrolled · Mexico
- Jun 6, 2019Rose Research Center's first study: phase 4 study in Smoking CessationNew to Rose Research CenterRose Research Center · NCT04188106 · 26 enrolled · United States
- Jul 25, 2019Phase 3 study in Dry Eye SyndromesViatris · NCT04036292 · 758 enrolled · United States
- Aug 27, 2019Phase 1 study in Healthy SubjectsViatris · NCT04072146 · 22 enrolled · United States
- Dec 4, 2019Phase 3 study in Smoking CessationRose Research Center · NCT04210180 · 25 enrolled · United States
- Jun 28, 2021Phase 2 study in Neurotrophic KeratopathyViatris · NCT04957758 · 113 enrolled · United States
- May 13, 2022Corxel Pharmaceuticals's first study: phase 3 study in Dry Eye SyndromesNew to Corxel PharmaceuticalsCorxel Pharmaceuticals · NCT05378945 · 340 enrolled · China
- Sep 27, 2022Phase 1 study in Dry Eye SyndromesCorxel Pharmaceuticals · NCT05576415 · 9 enrolled · China
- Apr 17, 2026Kriya Therapeutics's first study: phase 2 study in Trigeminal NeuralgiaNew to Kriya TherapeuticsKriya Therapeutics · NCT07596485 · 24 planned · Canada
Ahead
- Feb 2029Primary completion: phase 2 study in Trigeminal NeuralgiaKriya Therapeutics · NCT07596485
TargetBeta
“Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cytisinerule | Achieve Life Sciences | phase 3 | 13 |
Studies
All 44 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07596485Trigeminal Neuralgia · Canada | 2 | Recruiting | Kriya Therapeutics | Feb 2029 | 24 |
| NCT05576415Dry Eye Syndromes · China | 1 | Completed | Corxel Pharmaceuticals | Apr 27, 2023 | 9 |
| NCT05378945Dry Eye Syndromes · China | 3 | Completed | Corxel Pharmaceuticals | Apr 4, 2023 | 340 |
| NCT04957758Neurotrophic Keratopathy · United States | 2 | Completed | Viatris | Jan 27, 2023 | 113 |
| NCT04210180Smoking Cessation · United States | 3 | Completed | Rose Research Center | Oct 14, 2020 | 25 |
| NCT04072146Healthy Subjects · United States | 1 | Completed | Viatris | Nov 15, 2019 | 22 |
| NCT04036292Dry Eye Syndromes · United States | 3 | Completed | Viatris | Apr 10, 2020 | 758 |
| NCT04188106Smoking Cessation · United States | 4 | Completed | Rose Research Center | Dec 15, 2019 | 26 |
| NCT03873246Dry Eye Syndromes · Mexico | 2 | Completed | Viatris | Jan 7, 2020 | 123 |
| NCT03688802Dry Eye Syndromes · United States | 2 | Completed | Viatris | Sep 30, 2019 | 18 |
| NCT03636061Dry Eye Syndromes · United States | 2 | Completed | Viatris | Sep 26, 2018 | 182 |
| NCT01574703Smoking Cessation · United States, Argentina, Australia and more | 4 | Completed | Pfizer | Jul 2015 | 4,595 |
| NCT01456936Smoking Cessation · United States, Argentina, Australia and more | 4 | Completed | Pfizer | Jan 2015 | 8,144 |
| NCT01370356Smoking Cessation · United States, Australia, Canada and more | 4 | Completed | Pfizer | Jul 2013 | 1,510 |
| NCT01312909Smoking Cessation · United States, Canada, Georgia and more | 4 | Completed | Pfizer | Jan 2018 | 312 |
| NCT01244061Smoking Cessation · United States, Australia, Belgium and more | 4 | Completed | Pfizer | Nov 2012 | 498 |
| NCT01078298Smoking Cessation · United States, Bosnia and Herzegovina, Croatia and more | 4 | Completed | Pfizer | Jun 2012 | 525 |
| NCT00889720Smoking Cessation · France, Italy | 4 | Completed | Pfizer | Jul 2010 | 16 |
| NCT00749944Smoking Cessation · United States | 4 | Completed | Pfizer | Jul 2009 | 110 |
| NCT00744978Alzheimer Disease · Korea, Republic of | 2 | Completed | Pfizer | Nov 2010 | 66 |
| NCT00743847Schizophrenia | 2 | Withdrawn | Pfizer | Nov 2009 | 0 |
| NCT00717093Tobacco Use Cessation · Norway, Sweden | 4 | Completed | Pfizer | Apr 2009 | 432 |
| NCT00694044Healthy · United States | 1 | Completed | Pfizer | Jun 2008 | 50 |
| NCT00691483Smoking Cessation · United States, Argentina, Brazil and more | 4 | Completed | Pfizer | Sep 2009 | 659 |
| NCT00661765Smoking Cessation · United States | 1 | Completed | Pfizer | Jun 2008 | 18 |
| NCT00644969Smoking Cessation · United States, Canada | 3 | Completed | Pfizer | Apr 2010 | 128 |
| NCT00635401Smoking · Japan | 2 | Completed | Pfizer | 30 | |
| NCT00594204Smoking Cessation · Brazil, Colombia, Costa Rica and more | 4 | Completed | Pfizer | Jun 2009 | 593 |
| NCT00527150Smoking Cessation · United States | 1 | Completed | Pfizer | Feb 2008 | 48 |
| NCT00463918Smoking Cessation · United States, United Kingdom | 1 | Completed | Pfizer | 73 | |
| NCT00452894Smoking · China | 1 | Completed | Pfizer | 14 | |
| NCT00371813Smoking Cessation · China, Singapore, Thailand | 3 | Completed | Pfizer | 334 | |
| NCT00301145Unspecified Adult Solid Tumor, Protocol Specific · United States | – | Completed | SRI International | Jun 2008 | 1,200 |
| NCT00282984Smoking Cessation · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Nov 2007 | 714 |
| NCT00150254Smoking Cessation · United States | 2 | Completed | Pfizer | 625 | |
| NCT00150241Smoking Cessation · United States | 2 | Completed | Pfizer | 625 | |
| NCT00150228Smoking Cessation · United States | 2 | Completed | Pfizer | 300 | |
| NCT00143364Smoking Cessation · United States | 3 | Completed | Pfizer | 1,005 | |
| NCT00143325Smoking Cessation · United States, Belgium, France and more | 3 | Completed | Pfizer | 730 | |
| NCT00143299Smoking Cessation · United States, Australia | 3 | Completed | Pfizer | 375 | |
| NCT00143286Smoking Cessation · United States, Canada, Czech Republic and more | 3 | Completed | Pfizer | 2,000 | |
| NCT00141206Smoking Cessation · United States | 3 | Completed | Pfizer | 1,005 | |
| NCT00141167Smoking Cessation · Korea, Republic of, Taiwan | 3 | Completed | Pfizer | 250 | |
| NCT00139750Smoking Cessation · Japan | 2 | Completed | Pfizer | 600 |
How it is read
Names in the registry
- “varenicline”, 11 entries
- “Varenicline Tartrate”, 7 entries
- “Varenicline”, 6 entries
- “varenicline (CP-526,555)”, 6 entries
- “CP-526,555 (varenicline)”, 4 entries
Conditions, from the studies’ own filings
- Smoking Cessation, 28 studies
- Dry Eye Syndromes, 6 studies
- Smoking, 2 studies
- Trigeminal Neuralgia, 1 study
- Cigarette Smoking, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.